Literature DB >> 18978515

Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.

Tsutomu Saji1, Makoto Nakazawa, Kensuke Harada.   

Abstract

A questionnaire study was performed to determine the current status of palivizumab prophylaxis against respiratory syncytial virus infection in Japanese children with congenital heart disease <2 years of age. Palivizumab prophylaxis decreased the respiratory syncytial virus hospitalization rate by 42.8%.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18978515     DOI： 10.1097/INF.0b013e3181801d76

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  3 in total

1.  Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey.

Authors:  Jo Won Jung
Journal:  Korean J Pediatr       Date:  2011-05-31

2.  Managing the morbidity associated with respiratory viral infections in children with congenital heart disease.

Authors:  Joseph M Geskey; Stephen E Cyran
Journal:  Int J Pediatr       Date:  2012-02-29

3.  Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases.

Authors:  Ah Young Kim; Se Yong Jung; Jae Young Choi; Gi Beom Kim; Young-Hwue Kim; Woo Sup Shim; I-Seok Kang; Jo Won Jung
Journal:  Korean Circ J       Date:  2016-09-28       Impact factor: 3.243
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.